UNSPSC 51292002: Amiflamine

This classification denotes a monoamine oxidase inhibitor with the molecular formula C12H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NE25WV9C8S, chemically known as benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-, (s) but generally known as amiflamine, which bears US NIH Compound Identifier 71221. European Medicines Agency schedules Amiflamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05428MIG.

UNSPSC 51292002 Amiflamine is a Commodity code that covers pharmaceutical products, though recent state and local solicitations posted under this code show limited direct procurement of amiflamine itself and instead reflect broader pharmaceutical supply activities including naloxone, drug deactivation systems, and generic multi-source pharmaceuticals distributed through state and cooperative purchasing networks. State and local governments buy under this code through health departments, cooperative purchasing alliances, and county health agencies seeking to stock emergency pharmaceuticals, support community health initiatives, and manage pharmacy benefit programs. Issuing bodies range from single counties to multistate cooperative purchasing organizations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, and Seminole County, Florida have posted recent opportunities, with Texas Health and Human Services Commission also exploring direct-to-manufacturer prescription models.

Recent activity spans Florida, Minnesota, Texas, and Oregon (as a participating MMCAP member). Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, with bids due July 26, 2023, on a fixed-fee basis with a two-year term and one-year renewal option. Minnesota's MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and awards effective July 1, 2026; vendors must work through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with cGMP and DSCSA standards. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without a formal bidding timeline, positioning this as exploratory research ahead of future formal procurement.